Skip to search boxSkip to navigationSkip to main content

Clinical Pathway for the Diagnosis and Management of Patients With Relapsing–Remitting Multiple Sclerosis: A First Proposal for the Peruvian Population

  • César Caparó-Zamalloa
    ,
  • ,
  • Nicanor Mori
    ,
  • Wenzel Ivan Dueñas-Pacheco
    ,
  • Andrely Huerta-Rosario
    ,
  • Chandel Farroñay-García
Research Output:
Contribution to journal
Review article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Review article
Peer-review

Original language

English

Article number

667398

Journal (Volume, Issue Number)

Frontiers in Neurology (Volume 12)

Publication milestones

  • Published - 21/10/2021

Publication status

Published - 21/10/2021

Publication IDs

  • Scopus: 85118653057

Abstract

Background: Relapsing–remitting multiple sclerosis (RRMS) is a subtype of degenerative inflammatory demyelinating disease of multifactorial origin that affects the central nervous system and leads to multifocal neurological impairment. Objectives: To develop a clinical pathway (CP) for the management of Peruvian patients with RRMS. Methods: First, we performed a literature review using Medline, Embase, Cochrane, ProQuest, and Science direct. Then, we structured the information as an ordered and logical series of five topics in a defined timeline: (1) How should MS be diagnosed? (2) How should a relapse be treated? (3) How should a DMT be initiated? (4) How should each DMT be used? and (5) How should the patients be followed? Results: The personnel involved in the care of patients with RRMS can use a series of flowcharts and diagrams that summarize the topics in paper or electronic format. Conclusions: We propose the first CP for RRMS in Peru that shows the essential steps for diagnosing, treating, and monitoring RRMS patients based on an evidence-based medicine method and local expert opinions. This CP will allow directing relevant clinical actions to strengthen the multidisciplinary management of RRMS in Peru.

Funding Details

Conflict of Interest: The authors declare that this study received funding from Hoffmann-La Roche Pharmaceutical. The funder had the following involvement in the study: provided financing for the execution and publication of the clinical pathway.
FundersFunding numbers
Hoffmann-La Roche Pharmaceutical
-

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Social media
31
Captures
10